Novel Compounds to Inhibit Cancer, Cancer Metastasis, and Autoimmune Diseases

Tech ID:

Several candidate small molecules have been discovered that show dose-dependent anti-cancer effects in vitro.  These compounds each have one of the following characteristics: (1) non-hydrolyzable ATP analog or (2) adenosine receptor antagonist.  Testing of these compounds has demonstrated successful inhibition of cancer cell migration. Additionally, these compounds have shown efficacy in treating autoimmune diseases.



Bone metastasis is a serious consequence of many cancers and often proves to be fatal.  It is difficult to treat and is associated with symptoms that significantly reduce the patient’s quality of life: severe pain, fractures, and spinal cord compressions. Current bone cancer therapeutic options are problematic and are associated with other significant side-effects. Prevention of the metastasis would be a significant step forward in the successful treatment of these cancers.


Adenosine triphosphate (ATP) has been shown to have anti-cancer effects via its binding of P2 purigenic receptors.  Unfortunately, adenosine, the product of cellular enzymatic degradation of ATP, has been shown to have the opposite effect, stimulating tumor growth and migration though its activation of the adenosine receptor. Researchers at UT Health have discovered several small molecule compounds that inhibit metastasis in one of two different mechanisms.  The first group of compounds are analogs of ATP that cannot be hydrolyzed by the cellular ATPase enzyme. The second group of compounds are antagonists (deactivators) of the adenosine receptor.  Both sets of compounds have exhibited dose-dependent inhibition of breast cancer cell migration during in vitro cell migration assays. 


The same cellular mechanisms are involved in the production of IL-17. An increase in secretion of IL-17 by immune system cells has been linked to many autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Testing of these novel compounds showed a reduction in IL-17 secretion of 45-65%.


Commercial Applications & Advantages:

These novel small molecule compounds address an unmet need in both Oncology and  Immunology by providing a new treatment option with the promise of improved efficacy and outcomes over the existing therapeutics.


Note:   US Provisional application 62/574,329 is for the Autoimmune Disease indication.  All other filings are for Breast cancer.

For information contact:
Maryellen McCafferty
Business Development Manager
(210) 562-4001
Jean Jiang
Patent Information:

United States - Utility

Patent No.10,214,529

Status: Issued

Europe - National Phase

Patent No. 

Status: Pending

Canada - National Phase

Patent No. 

Status: Pending

China - National Phase

Patent No. 

Status: Issued